{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T08:52:08Z","timestamp":1780649528384,"version":"3.54.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s11102-025-01635-9","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T18:51:55Z","timestamp":1770663115000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Histopathological and radiological predictors of surgical remission failure in GH-secreting pituitary adenomas"],"prefix":"10.1007","volume":"29","author":[{"given":"R.","family":"Calandrelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"De Lucia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Chiloiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Vicari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. P.","family":"Mattogno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Valeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Doglietto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gaudino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"1635_CR1","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.1365-2265.2009.03667.x","volume":"72","author":"A Fernandez","year":"2010","unstructured":"Fernandez A, Karavitaki N, Wass JAH (2010) Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 72:377\u2013382. https:\/\/doi.org\/10.1111\/j.1365-2265.2009.03667.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1635_CR2","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/s1010-5182(02)00182-8","volume":"31","author":"S Dost\u00e1lov\u00e1","year":"2003","unstructured":"Dost\u00e1lov\u00e1 S, Sonka K, Smahel Z et al (2003) Cephalometric assessment of cranial abnormalities in patients with acromegaly. J Craniofac Surg 31:80\u201387. https:\/\/doi.org\/10.1016\/s1010-5182(02)00182-8","journal-title":"J Craniofac Surg"},{"key":"1635_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0071-6","volume":"5","author":"A Colao","year":"2019","unstructured":"Colao A, Grasso LFS, Giustina A et al (2019) Acromegaly. Nat Rev Dis Primers 5:20. https:\/\/doi.org\/10.1038\/s41572-019-0071-6","journal-title":"Nat Rev Dis Primers"},{"key":"1635_CR4","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1507\/endocrj.ej11-0177","volume":"59","author":"M Kato","year":"2012","unstructured":"Kato M, Inoshita N, Sugiyama T et al (2012) Differential expression of genes related to drug responsiveness between sparsely and densely granulated somatotroph adenomas. Endocr J 59:221\u2013228. https:\/\/doi.org\/10.1507\/endocrj.ej11-0177","journal-title":"Endocr J"},{"key":"1635_CR5","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s12022-008-9029-z","volume":"19","author":"A Obari","year":"2008","unstructured":"Obari A, Sano T, Ohyama K et al (2008) Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr Pathol 19:82\u201391. https:\/\/doi.org\/10.1007\/s12022-008-9029-z","journal-title":"Endocr Pathol"},{"key":"1635_CR6","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s11154-018-9465-0","volume":"19","author":"S Pedraza-Ar\u00e9valo","year":"2018","unstructured":"Pedraza-Ar\u00e9valo S, Gahete MD, Alors-P\u00e9rez E et al (2018) Multilayered heterogeneity as an intrinsic hallmark of neuroendocrine tumors. Rev Endocr Metab Disord 19:179\u2013192. https:\/\/doi.org\/10.1007\/s11154-018-9465-0","journal-title":"Rev Endocr Metab Disord"},{"key":"1635_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.648411","volume":"12","author":"M Puig-Domingo","year":"2021","unstructured":"Puig-Domingo M, Bernab\u00e9u I, Pic\u00f3 A et al (2021) Pasireotide in the personalized treatment of acromegaly. Front Endocrinol 12:648411. https:\/\/doi.org\/10.3389\/fendo.2021.648411","journal-title":"Front Endocrinol"},{"key":"1635_CR8","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s11102-016-0781-7","volume":"20","author":"DA Donoho","year":"2017","unstructured":"Donoho DA, Bose N, Zada G, Carmichael JD (2017) Management of aggressive growth hormone secreting pituitary adenomas. Pituitary 20:169\u2013178. https:\/\/doi.org\/10.1007\/s11102-016-0781-7","journal-title":"Pituitary"},{"key":"1635_CR9","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3171\/jns.1998.89.3.0353","volume":"89","author":"PU Freda","year":"1998","unstructured":"Freda PU, Wardlaw SL, Post KD (1998) Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. J Neurosurg 89:353\u2013358. https:\/\/doi.org\/10.3171\/jns.1998.89.3.0353","journal-title":"J Neurosurg"},{"key":"1635_CR10","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1530\/eje.0.1460707","volume":"146","author":"C Bruns","year":"2002","unstructured":"Bruns C, Lewis I, Briner U et al (2002) SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146:707\u2013716. https:\/\/doi.org\/10.1530\/eje.0.1460707","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1635_CR11","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1530\/eje.1.02350","volume":"156","author":"J van der Hoek","year":"2007","unstructured":"van der Hoek J, Lamberts SWJ, Hofland LJ (2007) Preclinical and clinical experiences with the role of somatostatin receptors in the treatment of pituitary adenomas. Eur J Endocrinol 156(1):S45\u2013S51. https:\/\/doi.org\/10.1530\/eje.1.02350","journal-title":"Eur J Endocrinol"},{"key":"1635_CR12","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1124\/pr.117.015388","volume":"70","author":"T G\u00fcnther","year":"2018","unstructured":"G\u00fcnther T, Tulipano G, Dournaud P et al (2018) International union of basic and clinical pharmacology. CV. somatostatin receptors: structure, function, ligands, and new nomenclature. Pharmacol Rev 70:763\u2013835. https:\/\/doi.org\/10.1124\/pr.117.015388","journal-title":"Pharmacol Rev"},{"key":"1635_CR13","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1210\/jc.2014-2700","volume":"99","author":"L Katznelson","year":"2014","unstructured":"Katznelson L, Laws ER, Melmed S et al (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99:3933\u20133951. https:\/\/doi.org\/10.1210\/jc.2014-2700","journal-title":"J Clin Endocrinol Metab"},{"key":"1635_CR14","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1056\/NEJM199004053221405","volume":"322","author":"S Melmed","year":"1990","unstructured":"Melmed S (1990) Acromegaly. N Engl J Med 322:966\u2013977. https:\/\/doi.org\/10.1056\/NEJM199004053221405","journal-title":"N Engl J Med"},{"key":"1635_CR15","doi-asserted-by":"publisher","DOI":"10.3171\/2010.7.FOCUS10155","volume":"29","author":"G Zada","year":"2010","unstructured":"Zada G, Lin N, Laws ER (2010) Patterns of extrasellar extension in growth hormone-secreting and nonfunctional pituitary macroadenomas. Neurosurg Focus 29:E4. https:\/\/doi.org\/10.3171\/2010.7.FOCUS10155","journal-title":"Neurosurg Focus"},{"issue":"3","key":"1635_CR16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1159\/000023538","volume":"53","author":"ER Laws","year":"2000","unstructured":"Laws ER, Vance ML, Thapar K (2000) Pituitary surgery for the management of acromegaly. Horm Res 53(3):71\u201375. https:\/\/doi.org\/10.1159\/000023538","journal-title":"Horm Res"},{"key":"1635_CR17","first-page":"195","volume":"150","author":"C Salaun","year":"1999","unstructured":"Salaun C, Foubert L, Vialatou M et al (1999) [Prognostic factors in the surgical management of acromegaly]. Ann Med Interne (Paris) 150:195\u2013198","journal-title":"Ann Med Interne (Paris)"},{"key":"1635_CR18","doi-asserted-by":"publisher","first-page":"6290","DOI":"10.1210\/jc.2005-0998","volume":"90","author":"S Bhayana","year":"2005","unstructured":"Bhayana S, Booth GL, Asa SL et al (2005) The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab 90:6290\u20136295. https:\/\/doi.org\/10.1210\/jc.2005-0998","journal-title":"J Clin Endocrinol Metab"},{"key":"1635_CR19","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1507\/endocrj1954.39.355","volume":"39","author":"H Bando","year":"1992","unstructured":"Bando H, Sano T, Ohshima T et al (1992) Differences in pathological findings and growth hormone responses in patients with growth hormone-producing pituitary adenoma. Endocrinol Jpn 39:355\u2013363. https:\/\/doi.org\/10.1507\/endocrj1954.39.355","journal-title":"Endocrinol Jpn"},{"key":"1635_CR20","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/s41379-018-0016-8","volume":"31","author":"O Mete","year":"2018","unstructured":"Mete O, Cintosun A, Pressman I, Asa SL (2018) Epidemiology and biomarker profile of pituitary adenohypophysial tumors. Mod Pathol Off J US Can Acad Pathol Inc 31:900\u2013909. https:\/\/doi.org\/10.1038\/s41379-018-0016-8","journal-title":"Mod Pathol Off J US Can Acad Pathol Inc"},{"key":"1635_CR21","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/j.1365-2265.2011.04163.x","volume":"76","author":"SL Fougner","year":"2012","unstructured":"Fougner SL, Casar-Borota O, Heck A et al (2012) Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin Endocrinol (Oxf) 76:96\u2013102. https:\/\/doi.org\/10.1111\/j.1365-2265.2011.04163.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1635_CR22","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s12020-015-0766-8","volume":"52","author":"A Heck","year":"2016","unstructured":"Heck A, Emblem KE, Casar-Borota O et al (2016) Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly. Endocrine 52:333\u2013343. https:\/\/doi.org\/10.1007\/s12020-015-0766-8","journal-title":"Endocrine"},{"key":"1635_CR23","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s11102-019-01020-3","volume":"23","author":"S Petersenn","year":"2020","unstructured":"Petersenn S, Houchard A, Sert C et al (2020) Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study. Pituitary 23:171\u2013181. https:\/\/doi.org\/10.1007\/s11102-019-01020-3","journal-title":"Pituitary"},{"key":"1635_CR24","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s11102-018-0877-3","volume":"21","author":"SC Dogansen","year":"2018","unstructured":"Dogansen SC, Yalin GY, Tanrikulu S et al (2018) Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas. Pituitary 21:347\u2013354. https:\/\/doi.org\/10.1007\/s11102-018-0877-3","journal-title":"Pituitary"},{"key":"1635_CR25","doi-asserted-by":"publisher","first-page":"379","DOI":"10.4158\/EP-2018-0500","volume":"25","author":"S Ezzat","year":"2019","unstructured":"Ezzat S, Caspar-Bell GM, Chik CL et al (2019) Predictive markers for postsurgical medical management of acromegaly: a systematic review and consensus treatment guideline. Endocr Pract 25:379\u2013393. https:\/\/doi.org\/10.4158\/EP-2018-0500","journal-title":"Endocr Pract"},{"key":"1635_CR26","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1097\/RCT.0000000000001249","volume":"46","author":"C-X Liu","year":"2022","unstructured":"Liu C-X, Wang S-Z, Heng L-J et al (2022) Predicting subtype of growth hormone pituitary adenoma based on magnetic resonance imaging characteristics. J Comput Assist Tomogr 46:124\u2013130. https:\/\/doi.org\/10.1097\/RCT.0000000000001249","journal-title":"J Comput Assist Tomogr"},{"key":"1635_CR27","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s11102-020-01077-5","volume":"23","author":"YW Park","year":"2020","unstructured":"Park YW, Kang Y, Ahn SS et al (2020) Radiomics model predicts granulation pattern in growth hormone-secreting pituitary adenomas. Pituitary 23:691\u2013700. https:\/\/doi.org\/10.1007\/s11102-020-01077-5","journal-title":"Pituitary"},{"key":"1635_CR28","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2147\/DDDT.S77999","volume":"10","author":"D Cuevas-Ramos","year":"2016","unstructured":"Cuevas-Ramos D, Fleseriu M (2016) Pasireotide: a novel treatment for patients with acromegaly. Drug Des Devel Ther 10:227\u2013239. https:\/\/doi.org\/10.2147\/DDDT.S77999","journal-title":"Drug Des Devel Ther"},{"key":"1635_CR29","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-18-0254","author":"F Bonneville","year":"2018","unstructured":"Bonneville F, Rivi\u00e8re L-D, Petersenn S et al (2018) MRI T2 signal intensity and tumor response in patients with GH-secreting pituitary macroadenoma: PRIMARYS post-hoc analysis. Eur J Endocrinol EJE. https:\/\/doi.org\/10.1530\/EJE-18-0254. -18-0254.R2","journal-title":"Eur J Endocrinol EJE"},{"key":"1635_CR30","doi-asserted-by":"publisher","first-page":"425","DOI":"10.15386\/mpr-1299","volume":"94","author":"C-L Sc\u00e2nteie","year":"2021","unstructured":"Sc\u00e2nteie C-L, Leucu\u0163a D-C, Ghervan C (2021) The therapeutic response of somatotropinomas according to the T2-weighted signal intensity on the MRI. Med Pharm Rep 94:425\u2013433. https:\/\/doi.org\/10.15386\/mpr-1299","journal-title":"Med Pharm Rep"},{"key":"1635_CR31","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s00234-016-1728-4","volume":"58","author":"M Shen","year":"2016","unstructured":"Shen M, Zhang Q, Liu W et al (2016) Predictive value of T2 relative signal intensity for response to somatostatin analogs in newly diagnosed acromegaly. Neuroradiology 58:1057\u20131065. https:\/\/doi.org\/10.1007\/s00234-016-1728-4","journal-title":"Neuroradiology"},{"key":"1635_CR32","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1530\/ERC-14-0305","volume":"22","author":"I Potorac","year":"2015","unstructured":"Potorac I, Petrossians P, Daly AF et al (2015) Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences. Endocr Relat Cancer 22:169\u2013177. https:\/\/doi.org\/10.1530\/ERC-14-0305","journal-title":"Endocr Relat Cancer"},{"key":"1635_CR33","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/j.1365-2265.2011.04286.x","volume":"77","author":"A Heck","year":"2012","unstructured":"Heck A, Ringstad G, Fougner SL et al (2012) Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clin Endocrinol (Oxf) 77:72\u201378. https:\/\/doi.org\/10.1111\/j.1365-2265.2011.04286.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1635_CR34","doi-asserted-by":"publisher","first-page":"4973","DOI":"10.1210\/jc.2010-0573","volume":"95","author":"M Puig-Domingo","year":"2010","unstructured":"Puig-Domingo M, Resmini E, Gomez-Anson B et al (2010) Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure. J Clin Endocrinol Metab 95:4973\u20134978. https:\/\/doi.org\/10.1210\/jc.2010-0573","journal-title":"J Clin Endocrinol Metab"},{"key":"1635_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ghir.2022.101502","volume":"67","author":"ET Durmu\u015f","year":"2022","unstructured":"Durmu\u015f ET, Atmaca A, Kefeli M et al (2022) Age, GH\/IGF-1 levels, tumor volume, T2 hypointensity, and tumor subtype rather than proliferation and invasion are all reliable predictors of biochemical response to somatostatin analogue therapy in patients with acromegaly: a clinicopathological study. Growth Horm IGF Res 67:101502. https:\/\/doi.org\/10.1016\/j.ghir.2022.101502","journal-title":"Growth Horm IGF Res"},{"key":"1635_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-021-00850-2","volume":"21","author":"M Dehghani","year":"2021","unstructured":"Dehghani M, Davoodi Z, Bidari F et al (2021) Association of different pathologic subtypes of growth hormone producing pituitary adenoma and remission in acromegaly patients: a retrospective cohort study. BMC Endocr Disord 21:186. https:\/\/doi.org\/10.1186\/s12902-021-00850-2","journal-title":"BMC Endocr Disord"},{"key":"1635_CR37","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/BF02739824","volume":"10","author":"D Voit","year":"1999","unstructured":"Voit D, Saeger W, L\u00fcdecke DK (1999) Pituitary adenomas in acromegaly: comparison of different adenoma types with clinical data. Endocr Pathol 10:123\u2013135. https:\/\/doi.org\/10.1007\/BF02739824","journal-title":"Endocr Pathol"},{"key":"1635_CR38","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/cen.14465","volume":"95","author":"L Heng","year":"2021","unstructured":"Heng L, Liu X, Jia D et al (2021) Preoperative prediction of granulation pattern subtypes in GH-secreting pituitary adenomas. Clin Endocrinol (Oxf) 95:134\u2013142. https:\/\/doi.org\/10.1111\/cen.14465","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1635_CR39","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1530\/eje.0.1500763","volume":"150","author":"A Bourdelot","year":"2004","unstructured":"Bourdelot A, Coste J, Hazebroucq V et al (2004) Clinical, hormonal and magnetic resonance imaging (MRI) predictors of transsphenoidal surgery outcome in acromegaly. Eur J Endocrinol 150:763\u2013771. https:\/\/doi.org\/10.1530\/eje.0.1500763","journal-title":"Eur J Endocrinol"},{"key":"1635_CR40","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/cen.14946","volume":"99","author":"S Ruiz","year":"2023","unstructured":"Ruiz S, Gil J, Biagetti B et al (2023) Magnetic resonance imaging as a predictor of therapeutic response to pasireotide in acromegaly. Clin Endocrinol (Oxf) 99:378\u2013385. https:\/\/doi.org\/10.1111\/cen.14946","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1635_CR41","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1210\/clinem\/dgac512","volume":"107","author":"M-D Ilie","year":"2022","unstructured":"Ilie M-D, Tabarin A, Vasiljevic A et al (2022) Predictive factors of somatostatin receptor ligand response in acromegaly-A prospective study. J Clin Endocrinol Metab 107:2982\u20132991. https:\/\/doi.org\/10.1210\/clinem\/dgac512","journal-title":"J Clin Endocrinol Metab"},{"key":"1635_CR42","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s12020-014-0383-y","volume":"49","author":"K Kiseljak-Vassiliades","year":"2015","unstructured":"Kiseljak-Vassiliades K, Carlson NE, Borges MT et al (2015) Growth hormone tumor histological subtypes predict response to surgical and medical therapy. Endocrine 49:231\u2013241. https:\/\/doi.org\/10.1007\/s12020-014-0383-y","journal-title":"Endocrine"},{"key":"1635_CR43","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1007\/s11102-020-01075-7","volume":"23","author":"EV Varlamov","year":"2020","unstructured":"Varlamov EV, Wood MD, Netto JP et al (2020) Cystic appearance on magnetic resonance imaging in bihormonal growth hormone and prolactin tumors in acromegaly. Pituitary 23:672\u2013680. https:\/\/doi.org\/10.1007\/s11102-020-01075-7","journal-title":"Pituitary"},{"key":"1635_CR44","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.3171\/2020.4.JNS193288","volume":"134","author":"MJ Rutkowski","year":"2021","unstructured":"Rutkowski MJ, Chang K-E, Cardinal T et al (2021) Development and clinical validation of a grading system for pituitary adenoma consistency. J Neurosurg 134:1800\u20131807. https:\/\/doi.org\/10.3171\/2020.4.JNS193288","journal-title":"J Neurosurg"},{"key":"1635_CR45","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s12022-016-9418-7","volume":"27","author":"W Saeger","year":"2016","unstructured":"Saeger W, Honegger J, Theodoropoulou M et al (2016) Clinical impact of the current WHO classification of pituitary adenomas. Endocr Pathol 27:104\u2013114. https:\/\/doi.org\/10.1007\/s12022-016-9418-7","journal-title":"Endocr Pathol"},{"key":"1635_CR46","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00401-013-1084-y","volume":"126","author":"J Trouillas","year":"2013","unstructured":"Trouillas J, Roy P, Sturm N et al (2013) A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 126:123\u2013135. https:\/\/doi.org\/10.1007\/s00401-013-1084-y","journal-title":"Acta Neuropathol"},{"key":"1635_CR47","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11102-023-01360-1","volume":"27","author":"A Giustina","year":"2024","unstructured":"Giustina A, Biermasz N, Casanueva FF et al (2024) Consensus on criteria for acromegaly diagnosis and remission. Pituitary 27:7\u201322. https:\/\/doi.org\/10.1007\/s11102-023-01360-1","journal-title":"Pituitary"},{"key":"1635_CR48","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s11102-023-01373-w","volume":"27","author":"A Giustina","year":"2024","unstructured":"Giustina A, Biermasz N, Casanueva FF et al (2024) Correction: consensus on criteria for acromegaly diagnosis and remission. Pituitary 27:88. https:\/\/doi.org\/10.1007\/s11102-023-01373-w","journal-title":"Pituitary"},{"key":"1635_CR49","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s11102-015-0684-z","volume":"19","author":"A Colao","year":"2016","unstructured":"Colao A, Auriemma RS, Pivonello R et al (2016) Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly. Pituitary 19:235\u2013247. https:\/\/doi.org\/10.1007\/s11102-015-0684-z","journal-title":"Pituitary"},{"key":"1635_CR50","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa387","volume":"105","author":"EC Coopmans","year":"2020","unstructured":"Coopmans EC, Korevaar TIM, van Meyel SWF et al (2020) Multivariable prediction model for biochemical response to first-generation somatostatin receptor ligands in acromegaly. J Clin Endocrinol Metab 105:dgaa387. https:\/\/doi.org\/10.1210\/clinem\/dgaa387","journal-title":"J Clin Endocrinol Metab"},{"key":"1635_CR51","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1007\/s11102-022-01217-z","volume":"25","author":"DJ Pangal","year":"2022","unstructured":"Pangal DJ, Wishart D, Shiroishi MS et al (2022) Growth hormone secreting pituitary adenomas show distinct extrasellar extension patterns compared to nonfunctional pituitary adenomas. Pituitary 25:480\u2013485. https:\/\/doi.org\/10.1007\/s11102-022-01217-z","journal-title":"Pituitary"},{"key":"1635_CR52","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ejrad.2018.05.009","volume":"104","author":"G Bier","year":"2018","unstructured":"Bier G, Hempel J-M, Grimm F et al (2018) Quantification of specific growth patterns and frequency of the empty sella phenomenon in growth hormone-secreting pituitary adenomas. Eur J Radiol 104:79\u201386. https:\/\/doi.org\/10.1016\/j.ejrad.2018.05.009","journal-title":"Eur J Radiol"},{"key":"1635_CR53","doi-asserted-by":"publisher","unstructured":"Calandrelli R, Pilato F, D\u2019Apolito G et al (2023) MRI and trouillas\u2019 grading system of pituitary tumors: the usefulness of T2 signal intensity volumetric values. https:\/\/doi.org\/10.1007\/s00234-023-03162-5. Neuroradiology","DOI":"10.1007\/s00234-023-03162-5"},{"key":"1635_CR54","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1210\/jc.2007-2104","volume":"93","author":"O Alexopoulou","year":"2008","unstructured":"Alexopoulou O, Bex M, Abs R et al (2008) Divergence between growth hormone and insulin-like growth factor-i concentrations in the follow-up of acromegaly. J Clin Endocrinol Metab 93:1324\u20131330. https:\/\/doi.org\/10.1210\/jc.2007-2104","journal-title":"J Clin Endocrinol Metab"},{"key":"1635_CR55","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/cen.13129","volume":"85","author":"GA Kanakis","year":"2016","unstructured":"Kanakis GA, Chrisoulidou A, Bargiota A et al (2016) The ongoing challenge of discrepant growth hormone and insulin-like growth factor I results in the evaluation of treated acromegalic patients: a systematic review and meta-analysis. Clin Endocrinol Oxf 85:681\u2013688. https:\/\/doi.org\/10.1111\/cen.13129","journal-title":"Clin Endocrinol Oxf"},{"key":"1635_CR56","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s42000-021-00302-5","volume":"20","author":"A Acitores Cancela","year":"2021","unstructured":"Acitores Cancela A, Rodr\u00edguez Berrocal V, Pian H et al (2021) Clinical relevance of tumor consistency in pituitary adenoma. Hormones 20:463\u2013473. https:\/\/doi.org\/10.1007\/s42000-021-00302-5","journal-title":"Hormones"},{"key":"1635_CR57","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1210\/jc.2014-2468","volume":"100","author":"D Cuevas-Ramos","year":"2015","unstructured":"Cuevas-Ramos D, Carmichael JD, Cooper O et al (2015) A structural and functional acromegaly classification. J Clin Endocrinol Metab 100:122\u2013131. https:\/\/doi.org\/10.1210\/jc.2014-2468","journal-title":"J Clin Endocrinol Metab"},{"key":"1635_CR58","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1007\/s00701-014-2230-6","volume":"156","author":"S Sarkar","year":"2014","unstructured":"Sarkar S, Chacko AG, Chacko G (2014) An analysis of granulation patterns, MIB-1 proliferation indices and p53 expression in 101 patients with acromegaly. Acta Neurochir (Wien) 156:2221\u20132230. https:\/\/doi.org\/10.1007\/s00701-014-2230-6","journal-title":"Acta Neurochir (Wien)"},{"key":"1635_CR59","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s11102-013-0500-6","volume":"17","author":"S Chiloiro","year":"2014","unstructured":"Chiloiro S, Bianchi A, Doglietto F et al (2014) Radically resected pituitary adenomas: prognostic role of Ki 67 labeling index in a monocentric retrospective series and literature review. Pituitary 17:267\u2013276. https:\/\/doi.org\/10.1007\/s11102-013-0500-6","journal-title":"Pituitary"},{"key":"1635_CR60","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s11102-010-0242-7","volume":"13","author":"G Chacko","year":"2010","unstructured":"Chacko G, Chacko AG, Kovacs K et al (2010) The clinical significance of MIB-1 labeling index in pituitary adenomas. Pituitary 13:337\u2013344. https:\/\/doi.org\/10.1007\/s11102-010-0242-7","journal-title":"Pituitary"},{"key":"1635_CR61","doi-asserted-by":"publisher","DOI":"10.1530\/EC-25-0103","volume":"14","author":"M Araujo-Castro","year":"2025","unstructured":"Araujo-Castro M, Biagetti B, Men\u00e9ndez E et al (2025) Predictors of therapeutic failure in GH and prolactin co-secreting pituitary adenomas. Endocr Connect 14:e250103. https:\/\/doi.org\/10.1530\/EC-25-0103","journal-title":"Endocr Connect"},{"key":"1635_CR62","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s40618-020-01296-4","volume":"44","author":"M Araujo-Castro","year":"2021","unstructured":"Araujo-Castro M, Pascual-Corrales E, Mart\u00ednez-Vaello V et al (2021) Predictive model of surgical remission in acromegaly: age, presurgical GH levels and Knosp grade as the best predictors of surgical remission. J Endocrinol Invest 44:183\u2013193. https:\/\/doi.org\/10.1007\/s40618-020-01296-4","journal-title":"J Endocrinol Invest"},{"key":"1635_CR63","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1148\/radiol.2282020695","volume":"228","author":"A Hagiwara","year":"2003","unstructured":"Hagiwara A, Inoue Y, Wakasa K et al (2003) Comparison of growth hormone-producing and non-growth hormone-producing pituitary adenomas: imaging characteristics and pathologic correlation. Radiology 228:533\u2013538. https:\/\/doi.org\/10.1148\/radiol.2282020695","journal-title":"Radiology"},{"key":"1635_CR64","doi-asserted-by":"publisher","first-page":"e130","DOI":"10.1016\/j.wneu.2018.09.127","volume":"122","author":"Y Hayashi","year":"2019","unstructured":"Hayashi Y, Sasagawa Y, Oishi M et al (2019) Directional regulation of extrasellar extension by sellar dura integrity and intrasphenoidal septation in pituitary adenomas. World Neurosurg 122:e130\u2013e138. https:\/\/doi.org\/10.1016\/j.wneu.2018.09.127","journal-title":"World Neurosurg"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-025-01635-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-025-01635-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-025-01635-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T17:38:08Z","timestamp":1773682688000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-025-01635-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1635"],"URL":"https:\/\/doi.org\/10.1007\/s11102-025-01635-9","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"29 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39"}}